论文部分内容阅读
近来,许多临床试验采用重组型组织型纤溶酶原活化剂(rt-PA)或链激酶进行静脉内溶栓,治疗急性心肌梗塞,结果表明可降低其死亡率,同时对左室功能具有保护作用.该治疗已在大的医疗中心实施.而本文着重描述在基层医院(com-munity)开展溶栓治疗的有关问题.病人选择珍妮医院是具有150张床位的基层医院,接受rt-PA治疗的对象均为该院的急性心肌梗塞患者,症状在6小时之内;持续的胸痛;具有两个以上邻近导联ST段抬高;无使用rt-PA禁忌症且年龄小于75岁.
Recently, many clinical trials of intravenous thrombolysis using recombinant tissue-type plasminogen activator (rt-PA) or streptokinase in the treatment of acute myocardial infarction have shown to reduce their mortality and at the same time have a protective effect on left ventricular function This treatment has been implemented in a large medical center, and this article focuses on issues related to thrombolytic therapy in com-munity Patient Choice Jenny Hospital is a 150-bed primary hospital receiving rt-PA Of patients were hospitalized with acute myocardial infarction with symptoms within 6 hours; persistent chest pain; ST segment elevation with two or more adjacent leads; no contraindications to rt-PA and were younger than 75 years.